BI 655066 Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis-2 (UltIMMa-2)

Trial Profile

BI 655066 Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis-2 (UltIMMa-2)

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Aug 2018

At a glance

  • Drugs Risankizumab (Primary) ; Ustekinumab
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms UltIMMa-2
  • Sponsors AbbVie; Boehringer Ingelheim
  • Most Recent Events

    • 10 Aug 2018 Results of pooled data from two trial (UltIMMa-1 and UltIMMa-2), were published in the The Lancet.
    • 01 May 2018 According to an AbbVie media release, the company has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for risankizumab, an investigational interleukin-23 (IL-23) inhibitor, being evaluated for the treatment of patients with moderate to severe plaque psoriasis. MAA was supported by data from ultIMMA-1, ultIMMa-2, IMMhance and IMMvent studies.
    • 25 Apr 2018 According to an AbbVie media release, the the company has submitted Biologics License Application to U.S. FDA for investigational treatment of Risankizumab for moderate to severe plaque psoriasis. The BLA was supported by data from ultIMMA-1, ultIMMa-2, IMMhance and IMMvent studies.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top